Inertia is the Competition, Not Another Drug - Return On Focus Return On Focus --- --- Return On Focus

    Inertia is the Competition, Not Another Drug

    Inertia is the Competition, Not Another Drug

    October 13, 2011

    When you’re thinking about the competitive set for your brand, you should ask yourself two very important questions:

    • What are the products that your brand directly and indirectly competes with for market- and mindshare?
    • What other factors influence physician decision making as it directly relates to your brand?

    Let me tell you a little bit more about this second one. A key pattern that we are seeing here at ROF over the last 12 months across a number of our clients is that the major competitive threat in their category is NOT another drug, procedure, or device. It’s inertia.

    Whether it’s physicians, patients, or managed care, the power of ingrained thinking is a significant challenge to most brand teams. It can be seen across a range of categories such as RA where anti-TNF cycling predominates and asthma where step therapy is dictated by the guidelines.

    It is critical that you consider these alternative external influences when thinking about the competition for your brand. They can have a significant impact on your strategy, objectives, and even messaging.

    Who is your brand really competing against?

    No Comments »

    No comments yet.

    RSS feed for comments on this post. TrackBack URL

    Leave a comment

    Follow us on
    Pinterest Twitter slideshare
    Contact Us

    Powered by WordPress